What the Gut Microbiome and Muscle Evidence Shows in Humans

The link between the gut microbiome and muscle growth is demonstrated in mice but unproven in humans. At Longevity Benchmark, we separate what research supports from marketing. Germ-free mice show reduced muscle mass and altered neuromuscular gene expression. In contrast, human research consists of observational correlations and small trials with mixed results.

Observational cohorts associate specific gut bacteria with higher appendicular lean mass and physical performance. These observational correlations cannot prove causation. They may simply reflect diet and physical activity. Furthermore, interventional trials adding probiotics to structured resistance training show modest benefits for strength but largely null effects on muscle hypertrophy.

The Gut Microbiome and Muscle Evidence Base

Current scientific evidence demonstrates a gut-muscle connection in rodent models that does not yet translate to proven human muscle growth.

The biological hypothesis linking the gut microbiome and muscle rests on three distinct evidence tiers. In rodent experiments, raising mice in sterile environments lacking any microbiota causes measurable muscle atrophy. In human observational research, researchers identify statistical correlations between specific bacterial taxa and appendicular lean mass. In human randomised controlled trials (RCTs), testing whether altering gut bacteria increases muscle mass produces conflicting or negative results.

Marketing campaigns frequently conflate these separate tiers. When wellness brands claim that a probiotic increases lean tissue, they typically extrapolate from germ-free rodent models. Alternatively, they cite cross-sectional human surveys that cannot establish cause. Human intervention trials show that when participants perform progressive resistance training, adding a microbial supplement provides no additional muscle gain beyond protein and training alone.

Skeletal Atrophy in Germ-Free Mouse Models

Laboratory mice raised without any gut bacteria develop marked skeletal muscle atrophy and impaired neuromuscular signalling.

In a landmark 2019 study published in Science Translational Medicine, Lahiri and colleagues compared germ-free mice lacking gut microbiota against pathogen-free mice carrying a normal microbiome. The skeletal muscle of germ-free mice showed distinct atrophy. The animals exhibited decreased expression of insulin-like growth factor 1 (IGF-1) alongside reduced transcription of genes supporting muscle growth and mitochondrial function. Nuclear magnetic resonance (NMR) spectrometry revealed multiple changes in the amounts of amino acids, including glycine and alanine, across skeletal muscle, liver, and serum.

Neuromuscular signalling was also impaired in the sterile mice. The researchers noted reduced serum choline, the direct precursor to acetylcholine, which serves as the primary neurotransmitter communicating between nerves and muscles. Germ-free skeletal muscle showed lower expression of genes encoding Rapsyn and Lrp4, two structural proteins required to assemble neuromuscular junctions. The authors measured muscle mass, metabolic enzymes, and gene expression; they did not measure grip strength or mechanical muscle force.

Restoring gut bacteria reversed these deficits. Transplanting gut microbiota from pathogen-free mice into germ-free recipients increased skeletal muscle mass, lowered atrophy markers, and elevated Rapsyn and Lrp4 expression. Furthermore, treating sterile mice with short-chain fatty acids partly reversed their muscle impairments. The authors hedged their conclusions carefully, stating that their findings suggest a regulatory role in mice.

Short-Chain Fatty Acid Mechanisms in Skeletal Tissue

Bacterial fermentation of dietary fibre produces short-chain fatty acids that influence host metabolism through distinct cellular pathways.

Anaerobic intestinal bacteria ferment complex carbohydrates reaching the cecum, yielding 400 to 600 mmol of short-chain fatty acids (SCFAs) daily. Total SCFA concentration reaches 70 to 140 mM in the proximal colon and 20 to 70 mM in the distal colon. Acetate, propionate, and butyrate appear in an approximate molar ratio of 60:20:20 in stool. In humans, SCFAs provide roughly 10 percent of total daily caloric requirements. Typical Western diets supply 20 to 25 grams of dietary fibre daily, whereas high-vegetable diets can reach 60 grams per day.

The cellular mechanisms linking SCFAs to peripheral tissue are well characterised. In a 2016 review in Cell, Koh and colleagues explained that SCFAs directly activate G-protein coupled receptors, inhibit histone deacetylases, and serve as direct oxidative energy substrates. Readers interested in these mechanisms can examine our analysis of butyrate and metabolic health.

Translating these metabolic actions into human muscle mass remains challenging. One cross-sectional study examined 412 healthy Chinese children aged 6 to 9 years. Researchers measured fecal concentrations of butyrate and acetate. Higher levels correlated with higher appendicular lean mass on DXA. However, statistical mediation analysis revealed that total body fat accounted for 66.3 to 95.3 percent of that association. After researchers adjusted for body fat or body mass index, the statistical relationship between SCFAs and lean mass vanished. To date, we found no human randomised controlled trial demonstrating that oral butyrate or SCFA supplements increase muscle mass or physical strength.

Human Observational Studies on Gut Bacteria and Strength

Large observational cohorts link specific bacterial species to physical performance and lean mass, though these statistical associations cannot establish causation.

The largest observational investigation to date evaluated 5,196 Norwegian adults within the population-based HUNT study. Researchers identified three bacterial species, Coprococcus comes, Dorea longicatena, and Eubacterium ventriosum, whose presence reproducibly correlated with higher appendicular lean mass. Participants carrying all three organisms exhibited 0.80 kg higher appendicular lean mass than those carrying none. The authors explicitly stated that the therapeutic potential of these species remains to be determined. The publication disclosed commercial competing interests: two authors were employed by and owned stock in Bio-Me, and another received research funding from Probi AB.

Smaller clinical cohorts show inconsistent bacterial patterns. A shotgun-metagenomics study of 17 older outpatients found that five sarcopenic individuals had depleted levels of Faecalibacterium prausnitzii and Roseburia inulinivorans. In contrast, an observational study of 164 Japanese adults identified a correlation between Bacteroides and leg extension power exclusively in participants aged 60 and older. That same study found zero correlation between gut bacteria and handgrip strength or skeletal muscle mass. In 207 community-dwelling older adults, higher fitness scores tracked with Bifidobacteriales and Clostridiales, but diet, exercise, and metabolomic markers together explained half the variance.

Genetic association studies offer supportive but preliminary data. A Mendelian randomisation study evaluated genetic proxies for sarcopenia traits, linking families like Alcaligenaceae and Paraprevotella to low handgrip strength risk, while eight taxa correlated with appendicular lean mass. The human gut-muscle axis remains unproven. A 2019 review in Nutrients by Ticinesi and colleagues concluded that the causal link between microbiota and physical fitness is still uncertain, because diet, exercise, multimorbidity and polypharmacy all act on both the microbiome and physical function in older age.

Human Randomised Trials on Probiotics and Resistance Training

Randomised clinical trials evaluating probiotics alongside resistance training show little evidence that microbial supplements accelerate human muscle hypertrophy.

The cleanest trial randomised 51 older men with type 2 diabetes, of whom 40 completed a supervised resistance-training program. Participants received either a protein supplement alone or protein combined with a synbiotic containing prebiotic fibre and probiotic strains. The trial found that adding the synbiotic provided no additional benefit for muscle mass or strength beyond the gains achieved by exercise and protein alone. Similarly, a 10-week trial in 23 Division I female athletes found that daily supplementation with Bacillus subtilis DE111 (5 billion colony-forming units) produced no improvement in physical performance compared to placebo.

Single-strain interventions in older adults show modest functional changes without lean tissue gains. A 12-week trial that randomised 119 adults aged 65 to 85, of whom 100 completed it, tested live and heat-treated Lacticaseibacillus paracasei PS23 against placebo. Both probiotic groups improved lower limb endurance and leg strength, but neither group showed any change in muscle mass or upper body strength. In another trial of 60 frail older adults, 13 weeks of prebiotic inulin and fructo-oligosaccharides improved handgrip strength and exhaustion scores, but the supplement failed to reduce overall clinical frailty rates.

Multi-ingredient formulations obscure probiotic effects in positive trials. A trial of 60 sarcopenic older adults reported significant gains in appendicular lean mass and handgrip strength following two months of a medical nutrition formula containing L. paracasei PS23. However, the formulation also contained 2.5 grams of leucine and 500 mg of omega-3 fatty acids. Because the probiotic was given together with leucine and omega-3, the trial could not isolate any independent contribution from the probiotic bacteria.

The Gut-Muscle Axis and Exercise-Driven Changes

Physical exercise directly alters gut microbial composition, proving that bacterial differences between athletes and sedentary individuals do not mean gut bacteria cause athletic ability.

The direction of causation runs heavily from physical activity toward the microbiome. In a 2014 study published in Gut, Clarke and colleagues studied professional athletes from an international rugby union squad with two control groups. The elite athletes exhibited significantly higher microbial diversity across 22 distinct bacterial phyla. However, higher diversity also positively correlated with protein consumption, reflecting accompanying dietary extremes. In a subsequent correspondence in Gut, Marlicz and Loniewski noted that extreme athletic diets confound cross-sectional microbiome comparisons.

Interventional trials confirm that exercise itself reshapes the microbiome. In a prospective study in Medicine and Science in Sports and Exercise, Allen and colleagues enrolled 32 previously sedentary adults (18 lean, 14 with obesity). Participants completed six weeks of supervised endurance exercise with strict dietary controls, followed by six weeks of sedentary washout. Exercise increased fecal concentrations of short-chain fatty acids in lean participants, but these microbial changes were largely reversed once exercise training ceased.

Commercial interests also shape public claims around athletic microbes. A 2019 paper in Nature Medicine by Scheiman and colleagues found more Veillonella in marathon runners after a race and isolated Veillonella atypica from their stool. Inoculating mice with that strain, or instilling propionate into the rectum, increased exhaustive treadmill run time. Those performance experiments were conducted entirely in rodents. That paper disclosed that two study authors co-founded FitBiomics, Inc., and that they and a third author held equity in FitBiomics, Inc.

Microbiome Sarcopenia Findings and Age-Related Loss Rates

Clinical diagnostic criteria define sarcopenia through objective functional strength and muscle mass thresholds rather than microbial biomarkers.

The European Working Group on Sarcopenia in Older People (EWGSOP2) published revised diagnostic standards in Age and Ageing. Clinical sarcopenia is identified as probable when muscle strength is low, confirmed when low muscle quantity or quality is detected, and severe when physical performance is impaired. Validated testing relies on calibrated handgrip dynamometry, dual-energy X-ray absorptiometry, and functional movement tests like gait speed. Readers can evaluate reference ranges in our breakdown of grip strength by age.

Scientific publications differ on how rapidly adults lose muscle mass with age. The EWGSOP2 consensus cites a leg muscle mass loss of 1 to 2 percent annually after age 50, alongside a 1.5 to 5 percent annual loss in strength. In contrast, a systematic review in Frontiers in Physiology by W. K. Mitchell reported median cross-sectional loss rates of 0.47 percent per year in men and 0.37 percent in women. Longitudinal studies cited by Mitchell showed loss rates of 0.64 to 0.98 percent annually at age 75, with muscle strength declining two to five times faster than muscle mass.

Maintaining muscle mass does not automatically protect functional force. In the prospective Health, Aging and Body Composition Study tracking 1,880 older adults over three years, leg strength declined by 2.6 to 4.1 percent per year, roughly three times faster than leg lean mass. Strikingly, gaining lean mass did not prevent age-related declines in muscle strength. Established medical management relies on resistance training and nutrition, not microbiome manipulation.

What the Evidence Does and Does Not Justify Doing

Human clinical trials do not justify taking probiotics, synbiotics, or fibre supplements to build muscle mass or physical strength. There is no target microbiome composition. A 2026 review concluded the gut microbiota acts as a context-dependent modulator rather than a primary causal driver of muscle decline.

In a randomised, triple-blinded trial of men aged 65 and over with type 2 diabetes, synbiotic supplementation provided no additional benefits beyond protein supplementation and resistance training alone. A randomised controlled trial in 23 Division I female athletes similarly found that probiotic consumption with post-workout nutrition had no effect on physical performance during a 10-week resistance-training programme.

Short-chain fatty acids are the end products of fermentation of dietary fibers by anaerobic intestinal microbiota. Western diets supply approximately 20 to 25 grams of fibre daily, while high fruit-and-vegetable diets reach 60 grams per day. However, we found no human randomised controlled trial testing butyrate or other short-chain fatty acids against muscle mass or strength endpoints. Dietary fibre is not a muscle intervention.

Clinical definitions rely instead on physical cut-points published by EWGSOP2. Its thresholds for low strength are a grip under 27 kilograms in men and under 16 kilograms in women, or more than 15 seconds for five chair rises. Its threshold for low physical performance is a gait speed of 0.8 metres per second or below. One human cohort study followed 1,880 older adults in the Health, Aging and Body Composition Study for three years. Leg strength fell about three times faster than leg lean mass, which dropped roughly 1 percent a year. Maintaining or gaining muscle mass did not prevent aging-associated declines in muscle strength. The trials that moved muscle outcomes tested resistance training and protein.

What a Stool Test Cannot Tell You About Muscle

Commercial gut microbiome testing panels cannot diagnose sarcopenia, assess skeletal muscle mass, or determine training capacity.

In draft guidance on scientific requirements for health claims related to muscle function, the European Food Safety Authority (EFSA) detailed clinical criteria for evaluating physical performance and muscle mass. The guidance document contains no mention of probiotics or the gut microbiota as recognized indicators of muscle health.

High dietary protein intake alters colonic bacterial metabolism, but these shifts do not impair muscle building. When protein escapes digestion in the small intestine, colonic bacteria ferment it in the distal colon into branched-chain fatty acids, ammonia, amines, phenols and sulfides, per a 2012 review by Windey and colleagues. A controlled feeding trial in 17 men showed that high-protein diets increased those fermentation products while lowering butyrate.

Athletes looking for a probiotic shortcut to hypertrophy will not find one here, and neither will older adults hoping a stool test can diagnose muscle loss. A double-blind randomised trial showing that an isolated probiotic increases muscle mass beyond resistance exercise and protein would change our verdict. Until that trial exists, the evidence supports three things: progressive resistance training, a measured baseline strength number to train against, and adequate daily protein. Our comparison of whey versus plant protein covers the sourcing question. A commercial gut panel answers none of them.

Related

• Evidence-based gut health research hub
• Butyrate and metabolic gut health
• Are commercial gut health tests accurate
• Handgrip strength reference ranges by age
• Whey versus plant protein comparison
• Creatine monohydrate clinical evidence